Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00713635 · ClinicalTrials.gov registry record

Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome

A clinical trial, sponsored by Columbia University.

Completed
Registry status
51
Enrollment target

NCT00713635: Completed study, sponsored by Columbia University.

NCT00713635 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00713635 has completed, sponsored by Columbia University.

COMPLETED
Registry status
51 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease.

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2010-12
Est. Completion 2016-01
Columbia University

958 total trials

What the finished NCT00713635 record still lists

NCT00713635 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00713635 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00713635 about?

NCT00713635 is a clinical study titled "Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome". The purpose of this study is to investigate the prenatal impact of abnormal cardiac structure on neurodevelopmental outcomes in children with congenital heart disease.

What is the current status of trial NCT00713635?

This trial is currently completed. The enrollment target is 51 participants. The study started on 2010-12. Estimated completion is 2016-01.

Who is sponsoring clinical trial NCT00713635?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00713635, the US trial registry maintained by the National Library of Medicine. NCT00713635 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.